The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination

[1]  I. Weissman,et al.  CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.

[2]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[3]  E. Felip,et al.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  yang-xin fu,et al.  CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors , 2015, Nature Medicine.

[5]  R. Majeti,et al.  A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells , 2015, mAbs.

[6]  I. Weissman,et al.  Macrophages are critical effectors of antibody therapies for cancer , 2015, mAbs.

[7]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[8]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[9]  D. Stuart,et al.  Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. , 2008, Molecular cell.